Announcements

Home/Announcements

Health Decisions, OncoBay Clinical, and TrialJectory Partner to Provide Specialized Clinical Development Services in Women’s Oncology

Durham, N.C., and Tampa, Fla., December 1, 2020 – Health Decisions, Inc., a full-service contract research organization (CRO) specializing in women’s health clinical research and diagnostic and medical device development, and OncoBay Clinical, Inc., a full-service boutique CRO specializing in complex, early-phase oncology programs, today announced a partnership to deliver specialized clinical development services for pharmaceutical and biotechnology companies developing therapeutics, medical devices, and diagnostics in oncology. As partners, Health Decisions and OncoBay Clinical will leverage deep expertise in women’s health and oncology to enhance clinical programs for sponsors investigating new treatment options in gynecologic oncology and breast cancer.

“A collaboration between OncoBay and Health Decisions provides a clear advantage to sponsors seeking development support in women’s oncology. Our combined understanding of female-centric clinical trials and the complexities of studies in oncology will enable strategic and flexible end-to-end solutions for our sponsor partners,” said Dr. Patrick Phillips, Chief Executive Officer of Health Decisions. “We believe the technical insight and operational agility created by combining our teams will allow us to accelerate clinical development activities, further supporting our mutual mission of improving the lives of patients around the world.”

“As a trusted oncology CRO, it was important for OncoBay to only form a collaboration with a best-in-class partner in women’s oncology that shared our vision and deep commitment to transform oncology research and positively impact cancer patients’ lives through innovation, collaboration, and partnership,” said Krystyna Kowalczyk, President and Chief Executive Officer of OncoBay Clinical. “We are honored to be partnered with Health Decisions, a long-standing and respected provider of clinical research services in the field of women’s health. Together, we look forward to delivering significant value to drug developers and physicians in their quest to cure women’s cancer.”

For many women, the first signs of cancer are discovered during routine visits to the gynecologist. Health Decisions and OncoBay will leverage a combined site network specialized in women’s health and oncology to expedite the identification of study participants. Health Decisions will also gain access to OncoBay’s unique technology ecosystem which includes a partnership with TrialJectory, a patient-first digital health company that uses artificial intelligence to curate large quantities of data produced by cancer research to match patients to clinical trials.

“With hundreds of thousands of women being diagnosed with cancer each year, it has become increasingly important to engage these patients where they are located and ensure access to the most advanced treatments for their exact diagnosis,” said Tzvia Bader, Chief Executive Officer and Co-Founder, TrialJectory. “Through the team’s vast expertise in women’s oncology needs, both OncoBay and Health Decisions, coupled with TrialJectory’s AI-powered digital health platform, are providing the next generation of cancer care to countless women in need.”

About Health Decisions

Health Decisions is a full-service contract research organization (CRO) offering therapeutic, operational, and regulatory excellence for the clinical development of drugs, medical devices, and combination drug/devices in indications that impact women profoundly and disproportionately. Based on years of experience and aided by a site network of more than 500 high-performing women’s health sites, Health Decisions delivers clinical studies tailored to meet sponsor, patient, and regulatory needs. More than 90 percent of the Health Decisions’ staff specialize in women’s health research, allowing for hand-selected study teams uniquely suited to address the challenges of developing assets in areas including reproductive and sexual health, menopause, pain management, osteoporosis, osteoarthritis, and gynecologic oncology. Additionally, Health Decisions conducts diagnostic and medical device studies in all therapeutic indications, including women’s health, oncology, and infectious disease. For more information, visit www.healthdec.com.

About OncoBay Clinical

OncoBay Clinical is a boutique contract research organization (CRO) specializing in immuno-oncology/cell therapy, offering full-service custom-curated CRO solutions for global pharmaceutical and biotech companies looking to advance their immuno-oncology product or device. As a wholly owned, for-profit subsidiary of Moffitt Cancer Center, OncoBay embeds scientific expertise, operational excellence and integrated cell manufacturing capabilities providing true end-to-end control. Built on years of IO and cell therapy expertise, a streamlined technology framework, a highly trained site network, and a dedicated team of experienced professionals, OncoBay is committed to operational excellence from start to finish. For more information, visit Oncobay.com and follow us on Facebook, Twitter and LinkedIn.

About TrialJectory

TrialJectory is a patient-first digital health company with a mission to democratize access to advanced cancer treatment. Recognized by TIME as one of “The 100 Best Inventions of 2020,” TrialJectory uses artificial intelligence (AI) to empower patients to own their cancer journey and analyzes its global patient community’s real-world data to empower cancer patients to make the most informed decisions about their care. For more information, please visit www.trialjectory.com, and follow the Company on Facebook, LinkedIn, Twitter, and Instagram.

Health Decisions, OncoBay Clinical, and TrialJectory Partner to Provide Specialized Clinical Development Services in Women’s Oncology2020-12-01T13:46:17+00:00

TIME Selects TrialJectory’s AI-Powered, Clinical Trial-Matching Platform for ‘100 Best Inventions of 2020’ List

Annual List Highlights Groundbreaking Inventions that Change How We Live and Make the World a Better Place

 

NEW YORKNov. 20, 2020 — TrialJectory (“the Company”), an AI-powered digital health platform that empowers cancer patients to find advanced new treatment options that fit their precise profiles, announced today that TIME has selected the Company’s patient-first, clinical trial-matching platform for its “100 Best Inventions of 2020” annual list.

“Millions of Americans are currently suffering from cancer while also facing major difficulties navigating the complex, jargon-y world of clinical trials. This is unacceptable since these trials often provide better alternatives and result in better outcomes than the standard of care,” said Tzvia Bader, CEO and co-founder, TrialJectory. “AI is the key to democratizing cancer care for all patients – no matter where they are located or their socioeconomic status – and this is at the heart of TrialJectory’s work. Through technology, for the first time ever, patients now have a clear voice and say in their treatment journey, allowing them to effectively partner with their oncologists to determine the best plan for their individual diagnoses.”

Completely free for cancer patients, TrialJectory’s platform mimics the mind of an oncologist to discover all available clinical trial information in a way that a single doctor does not have the time or ability to do on his or her own. In addition to trial-matching, TrialJectory’s Treatment Finder tool is the world’s first technology that allows cancer patients across the U.S. to view real-world treatment data from other patients who have the same medical profile – i.e., the same cancer type, the same stage, the same genetic mutations and biomarkers – along with the treatment’s outcome / remission rate, whether patients experienced disease progression or toxicity and much more.

TrialJectory SaaS intelligence platform, Patient Match Optimizer, allows pharmaceutical companies for the first time ever to identify patient barriers in their journey to participating in clinical trials. From operational to design barriers, the platform uncovers factors that go into a patient’s early decision-making process during clinical trial pre-screening, which can directly impact trial recruitment and retention, and uses real-time real-world patient data to identify gaps within the trial design. By giving Big Pharma and CROs visibility into the data and predicting areas for optimization, the platform enables Pharma to shorten the enrollment period, reduce costs, and expedite time to market, ultimately bringing lifesaving drugs to the market sooner for patients in need.

To assemble the “100 Best Innovations of 2020” list, TIME editors and correspondents around the world solicited nominations, which were then evaluated on key factors that included originality, creativity, effectiveness, ambition and impact.

TIME Selects TrialJectory’s AI-Powered, Clinical Trial-Matching Platform for ‘100 Best Inventions of 2020’ List2020-11-20T14:52:40+00:00

Welcoming former Deputy Chief Medical Officer for American Cancer Society, Dr. J. Leonard Lichtenfeld to Our Advisory Board

“Dr. Len”, as He is Well Known in the Oncology Community, Will Help Guide TrialJectory’s Continued Efforts to Democratize Access to Advanced Treatment for Patients Around the World.

New York, N.Y. – November 10, 2020TrialJectory, an AI-powered digital health platform that empowers cancer patients to find advanced new treatment options that fit their precise profile, announced today that it has appointed Dr. J. Leonard Lichtenfeld, MD, MACP, to the Company’s Clinical Advisory Board. Dr. Lichtenfeld previously served as the American Cancer Society’s Deputy Chief Medical Officer and has over four decades of in-depth cancer care experience across many aspects of cancer research and cancer care.

“Dr. Lichtenfeld, a nationally recognized leader in healthcare policy, will play a critical role in continuing to shape and inform TrialJectory’s offerings for cancer patients throughout the country, and across the globe,” said Tzvia Bader, CEO and Co-Founder, TrialJectory. “He understands how, through harnessing the power of technology, we can enable patients to take back control of their care and find advanced new treatments that are right for them. Furthermore, Dr. Lichtenfeld’s vast experience in preventing and detecting cancer early, improving patients’ quality of life and keeping his finger on the pulse of emerging cancer science and trends over the years will significantly help TrialJectory to provide patients with the tools that they need to successfully navigate their treatment journey.”

Dr. Lichtenfeld is a board-certified medical oncologist and internist who was a practicing physician for nearly two decades. In addition to previously serving as Deputy Chief Medical Officer for the American Cancer Society for many years, he continues to be deeply involved in healthcare policy at the local, state and national level. He graduated from the University of Pennsylvania and Hahnemann Medical College (now Drexel University’s College of Medicine), and his postgraduate training took place at Temple University Hospital in Philadelphia, as well as the Johns Hopkins University School of Medicine and National Cancer Institute in Baltimore.

“Given our shared mission of empowering cancer patients with transformational new technology, I am eager to join the TrialJectory team so that I can leverage my unique skill set to support their growth,” added Dr. Lichtenfeld. “Throughout my career, I’ve always actively sought out opportunities where I thought that I could make a meaningful impact on patients’ cancer journeys to improve outcomes and the quality of their lives. I look forward to helping bring this truly innovative AI platform into the hands of patients in need all over the globe at this pivotal time in TrialJectory’s evolution.”

 

Welcoming former Deputy Chief Medical Officer for American Cancer Society, Dr. J. Leonard Lichtenfeld to Our Advisory Board2020-11-18T21:59:09+00:00